Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Clinical Trial Grant

Duke Scholars

Principal Investigator Lindsay Anne Magura Rein Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Start Date

May 26, 2021

End Date

June 14, 2026

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Start Date

May 26, 2021

End Date

June 14, 2026